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MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector
domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin
remodeling proteins in acute leukemias. Here we demonstrate an alternative mechanism for activation of MLL following
fusions with proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil oligomerization domains
of these proteins are necessary and sufficient for leukemogenic transformation induced by the respective MLL fusion
proteins. Furthermore, homodimerization of MLL by synthetic dimerization modules mimics bona fide MLL fusion proteins
resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. Our studies support an oligomer-
ization-dependent mechanism for oncogenic conversion of MLL, presumably in part by recruitment of accessory factors
through the dimerized MLL moiety of the chimeric protein.
Introduction transdominant gene regulatory and leukemic potentials of MLL
(Ayton and Cleary, 2001). Simple truncation of MLL at the site
of translocation-induced fusion does not lead to developmentGeneration of chimeric transcription factors by chromosomal
translocations is a common pathogenetic mechanism in various of leukemias in gene-targeted mice (Corral et al., 1996) or in
retroviral transduction/transplantation models of MLL-associ-human malignances, particularly acute leukemias (Cleary, 1991;
Look, 1997; Rabbitts, 1994). A common target for chromosomal ated myeloid leukemogenesis (Lavau et al., 1997). MLL mutant
proteins resulting from chromosomal translocations are alwaysrearrangements is the mixed lineage leukemia gene, MLL, which
is mutated in 80% of infant and 10% of adult acute leukemias in-frame chimeras that reside in the nucleus, regardless of
whether the fusion partner is normally nuclear or cytoplasmic in(Djabali et al., 1992; Gu et al., 1992; Tkachuk et al., 1992; Ziemin-
van der Poel et al., 1991). It codes for a histone methyltransfer- origin (DiMartino and Cleary, 1999). Several MLL fusion partners
function as DNA binding transcription factors (forkhead proteinsase that has been reported to assemble in a supercomplex
containing several chromatin-modifying components and activi- AFX and FKHRL1) (Borkhardt et al., 1997; Hillion et al., 1997),
transcriptional coactivators (CBP and p300) (Ida et al., 1997;ties (Nakamura et al., 2002), suggesting a multifunctional role
in gene regulation. Remarkably, as a result of chromosomal Sobulo et al., 1997; Taki et al., 1997), or components of chroma-
tin remodeling machines (ENL is a component of EBAF) (Nie ettranslocations, MLL is fused with up to 50 different partner
proteins, which may be of either nuclear or cytoplasmic origin al., 2003). Structure/function studies of the respective fusion
proteins revealed that the minimal domains required for onco-(DiMartino and Cleary, 1999). There are no known unifying prop-
erties shared by this vast array of MLL fusion proteins in human genesis display transactivation potentials that vary from strong
(AFX, FKHRL1) (So and Cleary, 2002, 2003) to weak (ENL, ELL,leukemias. Thus, the diverse nature of MLL mutations suggests
that multiple molecular mechanisms may activate the oncogenic AF10, CBP) (DiMartino et al., 2000, 2002; Lavau et al., 2000; Luo
et al., 2001; Slany et al., 1998). Thus, acquisition of heterologouspotential of this multifunctional epigenetic regulator.
Although diverse mutations in leukemias could abrogate a transcriptional effector domains by MLL may represent a com-
mon oncogenic pathway for deregulating its transcriptionalpossible tumor suppressor role for MLL, several lines of evi-
dence support an important role for fusion partners in activating functions by some, if not all, of its nuclear fusion partners.
S I G N F I C A N C E
A remarkable number and variety of proteins undergo in-frame fusions with MLL as a consequence of chromosomal translocations
in acute leukemias, suggesting a diversity of mechanisms for the oncogenic activation of MLL, which normally functions as a histone
methyltransferase. Although MLL can be activated by acquisition of heterologous transcriptional effector domains following fusions
with various nuclear factors, most MLL fusion partners are cytoplasmic proteins with unknown effects on its function. Here we
demonstrate that simple dimerization of MLL by bona fide cytoplasmic or synthetic fusion partners activates its transcriptional and
oncogenic properties. These studies reveal a novel mechanism for oncogenic conversion of MLL and demonstrate that oligomerization
of a chimeric transcription factor leads to cellular transformation and myeloid leukemias.
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Figure 1. Cytoplasmic proteins AF1p and GAS7 activate the oncogenic properties of MLL but lack intrinsic transcriptional activation potential
A: Murine bone marrow cells were enriched for stem/progenitor cells by c-Kit-positive selection and transduced with retroviral constructs expressing proteins
that are schematically shown on the left. Bar graph (right) indicates numbers of colonies obtained at each round of serial replating in methylcellulose
cultures.
B: Survival curves are shown for cohorts (n  10) of sublethally irradiated C57BL/6 mice that were injected with cell lines immortalized by various MLL fusion
proteins or mock injected (Control).
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The majority of MLL fusion partners, however, are cyto- Table 1. Features of leukemic mice injected with MLL-GAS7 and MLL-AF1p
transformed cellsplasmic proteins with no known roles in transcriptional regula-
tion (DiMartino and Cleary, 1999). Most attempts to establish Control MLL-GAS7 MLL-AF1p
disease models for studying their leukemogenic mechanisms
Disease latency (days)* n.a. 106  45 93  31
have been unsuccessful (Fuchs et al., 2001; Strehl et al., 2003). WBC (103/l)* 6.9  1.2 61  48 50  41
Thus, little is known about the oncogenic properties of the re- Blasts in peripheral blood (%)* 0 42  21 42  33
Liver weight (mg)* 0.45  0.12 3.2  2.4 2.8  1.4spective MLL fusion proteins or how a protein that normally
Spleen weight (mg)* 0.12  0.03 0.69  0.35 0.62  0.28functions in the cytoplasm results in oncogenic activation of
*Values shown as mean  standard deviation.MLL. The potential roles of MLL fusion proteins are further com-
n.a., not applicable.plicated by observations that expression of an MLL-GAL fusion
protein in a knockin mouse model results in development of
acute myeloid leukemias, albeit with reduced penetrance and
long latencies (Dobson et al., 2000).
In this study, we demonstrate that homo-oligomerization EGF pathway substrate AF1p activates the in vitro oncogenic
(formation of complexes with two or more identical subunits) potential of MLL.
mediated by two different cytoplasmic proteins contributes to Cells transduced with MLL-AF1p also induced leukemias
the oncogenic activation of MLL. One of these partners, AF1p, in sublethally irradiated mice with short latencies (5 months)
was originally discovered as a substrate of the EGF receptor (Figure 1B). In pre-terminal leukemic mice, greater than 30% of
tyrosine kinase (Fazioli et al., 1993); the other, GAS7, functions BM cells were comprised of leukemic blasts, which were also
in undefined growth arrest pathways (Ju et al., 1998). Neither present in the peripheral blood and infiltrated the spleen and liver
protein possesses inherent transcriptional effector properties, (Figure 1C). Blasts consistently displayed a surface phenotype
but both contain coiled-coil domains that mediate homo-oligo- characteristic of myeloid progenitors (Figure 1D). The latencies
merization and are necessary and sufficient for activation of and presentations of leukemias arising in MLL-AF1p mice were
MLL. Furthermore, the transcriptional and growth-altering prop- similar to leukemias induced by MLL-GAS7 (So et al., 2003),
erties of MLL could be induced by fusion with synthetic dimer- another MLL fusion involving a cytoplasmic partner protein
ization modules. These studies reveal a novel mechanism for (Megonigal et al., 2000). Their comparative properties are sum-
oncogenic conversion of MLL and demonstrate that oligomer- marized in Table 1. Taken together, these results indicated that
ization of a chimeric transcription factor results in cellular trans- fusion of MLL with two different cytoplasmic proteins (AF1p or
formation and myeloid leukemia. GAS7) results in its oncogenic activation in vitro and in vivo.
Results
AF1p and GAS7 lack intrinsic transcriptional
activation potentialFusion with the EGF pathway substrate AF1p activates
Previous studies have consistently demonstrated that fusionthe leukemogenic properties of MLL
partners of MLL that normally reside in the nucleus possessTo assess the oncogenic ability of MLL-AF1p (Bernard et al.,
intrinsic transcriptional effector properties, which are required1994), it was expressed under control of the long terminal repeat
for oncogenic activation of MLL (DiMartino et al., 2000, 2002;(LTR) of the murine stem cell virus (MSCV) following transduction
Lavau et al., 2000; Luo et al., 2001; Slany et al., 1998; So andinto murine hematopoietic progenitors and stem cells. MSCV-
Cleary, 2002, 2003). Thus, AF1p and GAS7 were assessed forneo vector alone and retroviruses expressing the respective
potential transcriptional effector properties in transient tran-portions of MLL (MLL-5) or AF1p (AF1p-3) were also tested
scriptional assays following fusion to the Gal4 DBD. Under con-as controls (Figure 1A). Initial plating of transduced cells in
ditions in which two nuclear fusion partners of MLL (AFX andmethylcellulose media containing myeloid cytokines showed
FKHRL1) strongly activated expression of three different pro-similar numbers and morphologies of colonies for all constructs,
moters, Gal4-AF1p and Gal4-GAS7 did not exhibit any signifi-indicating comparable transduction efficiencies. In subsequent
cant transcriptional properties in transiently transfected 293platings, MLL-AF1p-transduced cells yielded increasing num-
(Figure 1E), COS7, or REH cells (data not shown). These databers of colonies with blast-type morphology, a phenotype con-
suggested that the pathogenic contributions of AF1p and GAS7,sistent with the enhanced self-renewal typically induced by
in contrast to those demonstrated for nuclear fusion partnersother MLL oncogenes. In contrast, cells transduced with control
of MLL, are unlikely to be based on an intrinsic ability to functionconstructs exhausted their self-renewal potentials by the sec-
ond plating. These results demonstrated that fusion with the as transcriptional activators.
C: Representative histology from leukemic MLL-AF1p mice. Paraffin sections were stained with H&E; blood smears were stained with May-Gru¨nwald-Giemsa
(MGG). In MLL-AF1p mice, the spleen and liver were heavily infiltrated with leukemic blasts. Bone marrow was densely packed with a homogeneous
population of blasts. Leukemic blasts were present in the peripheral blood and infiltrate the portal veins of liver of moribund MLL-AF1p mice.
D: FACS analysis shows that leukemic cells from MLL-AF1p mice display an early myeloid precursor phenotype. Shadow profiles represent FACS staining
obtained with antibodies specific for the indicated cell surface antigens. Red lines represent staining obtained with isotype control antibodies.
E: Gal4-AF1p and Gal4-GAS7 fusion proteins lack transactivation properties in transient transactivation assays. Normalized luciferase values are shown for
the average of three experiments using reporter genes under control of promoters for either the HSV thymidine kinase, adenoviral E1b, or myelomonocytic
growth factor receptor genes. Comparable expression levels of the Gal4 constructs were confirmed by Western blot analysis (data not shown).
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Figure 2. The coiled-coil domains of cytoplasmic
fusion partners AF1p and GAS7 are necessary
and sufficient for activation of MLL oncogenic
potential
A and B: Schematic diagrams on the left illustrate
various mutant forms of MLL-AF1p and MLL-GAS7
used for structure/function studies to map do-
mains required for in vitro transformation. Bar
graphs on the right indicate the number of colo-
nies obtained at the third round of serial replating
in methylcellulose cultures. EH, EH hands; Coil,
coiled-coil domain; DPF, DPF repeats; WW, WW
domain; FCH, Fer-CIP4 homology domain, which
overlaps with part of the coiled-coil domain of
GAS7.
The coiled-coil domains of MLL-AF1p and MLL-GAS7 the WW domain was transformation competent (Figure 2B).
Cells transduced with mutants containing only the FCH domainare required for transformation
Structure/function studies were conducted to identify the spe- (MLL-GAS7138-315) or with deletion of part of the coiled-coil do-
main (MLL-GAS7138-360 and MLL-GAS7185-412) exhausted their pro-cific domains in AF1p and GAS7 required for cellular transforma-
tion. Mutants of AF1p (Figure 2A) targeted three well-defined liferative capability after the first plating. Only constructs con-
taining the complete coiled-coil domain (MLL-GAS792-412 andfunctional motifs designated as EH hands, coiled-coil, and DPF
domains. Methylcellulose replating assays showed that the EH MLL-GAS7138-412) were able to sustain continued replating into
the third round of culture. Cells transduced by these latter mu-hands were neither necessary nor sufficient for in vitro transfor-
mation since a construct containing only this region (MLL- tants could be adapted to growth in liquid medium and induced
acute leukemias in sublethally irradiated syngeneic recipientAF1p12-305) yielded no third round colonies whereas a construct
lacking this region (MLL-AF1p302-896) induced robust transforma- mice, albeit with longer latencies (mean 12 months) and reduced
penetrance (50% at 18 months) compared to MLL-GAS7 (Figuretion (Figure 2A). Similar findings applied to the DPF domain.
Conversely, constructs lacking the coiled-coil domain were un- 1B). Thus, structurally similar domains (coiled-coil) of the unre-
lated AF1p and GAS7 proteins are sufficient to activate theable to enhance the clonogenic potential of progenitors in vitro
whereas all constructs containing this region were oncogenic oncogenic properties of MLL.
including MLL-AF1p302-594, which consisted exclusively of the
coiled-coil fused to MLL. These data indicated that the AF1p MLL-AF1p and MLL-GAS7 homo-oligomerize through
coiled-coil domain is critical for MLL-AF1p-mediated transfor- their coiled-coil domains
The coiled-coil domain of AF1p has been shown to mediatemation.
Mutants of MLL-GAS7 targeted the WW domain, FCH (Fer- its homodimerization (Cupers et al., 1997; Tebar et al., 1997),
whereas homo-oligomerization of GAS7 has been proposedCIP4 Homology) domain, and a C-terminal coiled-coil domain
(Figure 2B). The WW domain, which mediates binding to proline- (She et al., 2002) but not yet demonstrated. Therefore, a GST
pulldown assay was used to assess the dimerization potentialrich sequences, was dispensable for in vitro transformation (Fig-
ure 2B) since a mutant lacking this domain (MLL-GAS792-412) was of GAS7 in vitro. Full-length 35S-labeled GAS7 interacted with
GST-GAS7 but not GST alone, indicating that GAS7 is capableactive in the assay. Furthermore, a synthetic construct (MLL-
GAS7a) encoding an alternatively spliced form of GAS7 lacking of forming homo-oligomers in vitro (Figure 3A). Analysis of vari-
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ous GAS7 mutants indicated that an intact coiled-coil domain
was required and appeared sufficient for the observed interac-
tion. Similar results were obtained using an immunoprecipita-
tion/Western blot assay of COS7 cells that were cotransfected
with Flag-tagged full-length GAS7 and various His-tagged GAS7
mutants. Coprecipitation of Flag-tagged GAS7 was only ob-
served to occur with His-tagged GAS7 proteins containing an
intact coiled-coil (GAS71-412, GAS71a-336a, and GAS7138-412). His-
tagged mutants with complete or partial deletion of the coiled-
coil (GAS71-193, GAS7185-412, GAS7138-315, and GAS7138-360) failed to
coprecipitate Flag-tagged GAS7 (Figure 3B). Therefore, similar
to AF1p, the coiled-coil of GAS7 is capable of mediating homo-
oligomerization.
Immunoprecipitation/Western blot analysis was also used to
assess whether MLL-AF1p and MLL-GAS7 homo-oligomerize in
living cells. Lysates from 293 cells coexpressing Flag-tagged
and His-tagged MLL fusion proteins were immunoprecipitated
with anti-HIS antibodies, and the pellets subjected to Western
blot analysis with anti-Flag antibodies. Flag-tagged MLL-GAS7
coprecipitated with His-tagged MLL-GAS7 but not with MLL
lacking GAS7 sequences (His-MLL 5) (Figure 3C). Similarly,
Flag-tagged MLL-AF1p coprecipitated with His-tagged MLL-
AF1p if the coiled-coil domain was present in both constructs.
Taken together, our results indicate that MLL-AF1p and MLL-
GAS7 self-associate through their coiled-coil domains, which
are also necessary and sufficient for myeloid transformation
in vitro.
Dimerization of amino-terminal MLL is sufficient
to enhance the self-renewal of hematopoietic
progenitors
To test whether homodimerization may be sufficient to activate
MLL, synthetic dimerization modules were used to construct a
set of novel MLL fusion proteins (Figures 4A and 4B). Conditional
dimerization modules consisted of FKBP and FRB2098L, which
form heterodimers in the presence of the synthetic dimerizing
agent AP21967 (Chen et al., 1995; Choi et al., 1996). Transduc-
tion of either construct alone was unable to sustain the clono-
genic potential of myeloid progenitors in serial replating assays
in the presence of AP21967 (Figure 4A). However, cotransduc-
tion of MLL-FKBP with MLL-FRB resulted in enhanced genera-
tion of CFU-GM-like colonies in the third round of replating in
the presence but not absence of AP21967. To further address
the role of dimerization on its oncogenic potential, MLL was
separately fused with short (40 amino acid) amphipathic acidic
or basic leucine zippers, respectively, which have been shownFigure 3. The coiled-coil domains of AF1p and GAS7 mediate homo-oligo-
merization of MLL fusion proteins to mediate constitutive heterodimerization (Scott et al., 1996).
Primary myeloid progenitors transduced with either constructA: GST pulldown assays were performed with various portions of GAS7 (indi-
cated by horizontal bars on left), which were translated in vitro and incu- alone were unable to generate colonies beyond the first round
bated with GST (lane 2) or GST-GAS71-412 (lane 3). Bound proteins (generally of plating, while progenitors cotransduced with both constructs
1%–2% of input) were washed, eluted, and subjected to SDS-PAGE and
formed compact colonies in the third plating (Figure 4C). How-autoradiography. Radiolabeled input proteins are shown in lane 1.
ever, the colonies displayed reduced plating efficiencies com-B: In vivo homodimerization of GAS7. Anti-His tag immunoprecipitations
were performed on lysates of cells coexpressing Flag-tagged GAS7 and pared to MLL-GAS7 or MLL-AF1p transduced progenitors (Fig-
His-tagged mutant forms of GAS7 (indicated at top of lanes). Anti-Flag ure 4B versus Figure 1) and could not be sustained indefinitely,
Western blot analysis revealed that only constructs containing intact although all constructs expressed at similar levels in transducedcoiled-coil domains coprecipitated with full-length GAS7. Lower panels
demonstrate presence of HIS- and Flag-tagged proteins in transfected cell
lysates.
C: In vivo homodimerization of MLL-GAS7 and MLL-AF1p mediated by the
coiled-coil domains. Anti-His tag immunoprecipitations were performed on
blot analysis revealed that only constructs containing intact coiled-coillysates of cells coexpressing Flag-tagged MLL-GAS7 and His-tagged mu-
tants (indicated at the top of left panel) or Flag-tagged MLL-AF1p and His- domains coprecipitated with MLL-GAS7 or MLL-AF1p. Lower panels demon-
strate presence of HIS- and Flag-tagged proteins in transfected cell lysates.tagged mutants (indicated at the top of right panel). Anti-Flag Western
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Figure 4. Forced dimerization of amino-terminal MLL enhances the self-renewal properties of myeloid progenitors
A: Methylcellulose replating assays were performed on myeloid progenitors transduced with constructs encoding MLL-FKBP or MLL-FRB fusion proteins in
the presence () or absence () of dimerizing agent AP21967. Bar graph (right) indicates numbers of colonies obtained at the third round of replating in
methylcellulose cultures.
B: Results are shown for similar analysis of myeloid progenitors transduced with constructs encoding MLL fusion proteins containing acidic or basic leucine
zippers at their C termini (schematically illustrated on left).
C: Typical morphology is shown for methylcellulose colonies generated from progenitors cotransduced with retroviruses expressing MLL-FKBP and MLL-FRB,
in the presence (i) or absence (ii) of dimerizer AP21967, or MLL-zipper constructs (iii). Phenotypic analysis of cells cotransduced with MLL-zipper constructs
indicates a myeloid precursor phenotype. Shadow profiles represent FACS staining obtained with antibodies specific for the indicated cell surface antigens.
Black lines represent staining obtained with isotype control antibodies.
D: Detection of MLL fusion protein expression in Phoenix cells by Western blot analysis. WT 	 wild-type MLL proteins.
Phoenix cells (Figure 4D). FACS analysis of cells from these this domain by both members of the MLL dimer is critical for
transformation. Conversely, deletion of the AT-hook motifs didcultures showed features of myeloid precursors, which were
more mature than those of MLL-AF1p-transformed cells (Figure not eliminate clonogenic potential, indicating that these minor
groove DNA binding motifs are not absolutely required for MLL-4B and data not shown). These results indicated that dimeriza-
tion of MLL per se is capable of enhancing the self-renewal of dimer oncogenic function. Deletion of the conserved but func-
tionally obscure RERE/snRNP and Ala/Ser-rich (AS-rich) do-hematopoietic progenitors in vitro.
mains abolished clonogenic growth, suggesting that these
Distinct MLL functional domains are required domains also are critical for each member of the dimer. The
for enhanced self-renewal induced essential MLL domains revealed by these structure/function
by homodimerization studies are similar to those required by MLL-ENL (Chen et al.,
To investigate the mechanism of dimer-mediated transforma- 2002), indicating that MLL contributions to myeloid transforma-
tion, various mutations that targeted known structural or func- tion are similar for oncogenic pathways that are dependent
tional motifs were introduced into the MLL acidic zipper con- on MLL dimerization and those that appear to be dimerization
struct (Figure 5). These constructs were then cotransduced with independent.
an intact MLL basic zipper construct into primary myeloid pro-
genitors whose growth properties were evaluated in methylcel- MLL-GAS7 and MLL-AF1p activate Hox
gene expressionlulose serial replating assays. Point mutation or deletion (CXXC
or KFGG) that disrupted the DNA binding properties of the Although AF1p and GAS7 do not exhibit intrinsic transactivation
properties, we investigated the possibility that their respectivemethyltransferase homology domain (Chen et al., 2002) abro-
gated the ability of MLL homodimers to enhance progenitor MLL fusion proteins may activate transcription as a conse-
quence of dimerization. Transient transactivation assays wereself-renewal (Figure 5), suggesting that DNA binding through
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Figure 5. Mapping of MLL domains required for enhanced self-renewal ability induced by dimerization
Transformation assays were performed on progenitors cotransduced with constructs encoding synthetic MLL fusion proteins containing acidic or basic
C-terminal leucine zippers. Fusion proteins with acidic zippers contained mutations of various MLL motifs as indicated schematically on the left. Bar graph
(right) indicates numbers of colonies obtained at the third round of replating in methylcellulose cultures.
performed using 293 or REH cells coexpressing MLL-GAS7 or plays inherent transcriptional effector activity (Rubnitz et al.,
1994; Schreiner et al., 1999). These results suggested that MLLMLL-AF1p together with a reporter gene under control of the
HoxA7 promoter, which is a downstream target of MLL (Ka- fusions with cytoplasmic partners that mediate dimerization
have similar effects on downstream Hox gene expression inwagoe et al., 2001; Schreiner et al., 1999; Yu et al., 1995). Both
fusion proteins activated transcription by more than 50-fold transformed cells as MLL oncoproteins that recruit transcrip-
tional cofactors directly through the fusion partner moiety.(Figure 6A), whereas control constructs (MLL-5, AF1p-3,
GAS7) had much more modest effects. Similarly, cotransfection
of MLL acidic and basic zipper constructs led to strong trans- Discussion
activation compared to minimal activation by each alone (Figure
6A). Taken together, these results suggested that forced dimer- A distinguishing feature of MLL-associated leukemias is the
remarkable number and variety of partner proteins that undergoization created a transcriptional activator complex, presumably
through recruitment of unknown cofactors by the dimerized in-frame fusions with MLL as a consequence of chromosomal
translocations. This is likely to reflect a diversity of mechanismsMLL moiety, analogous to dimerization-mediated alterations of
transcriptional properties of other chimeric oncoproteins (Lin for oncogenic activation of MLL leading to different pathways
of acute leukemogenesis. Some MLL fusion partners are nuclearand Evans, 2000; Minucci et al., 2000).
To investigate the effects of MLL dimerization on target gene proteins that normally function as transcription factors, cofac-
tors, or components of chromatin remodeling machines, andexpression in transformed cells, we assessed the expression
of select Hox cluster genes and Hox cofactors, which are known deregulation of transcriptional activity through these partner
moieties is critical for a subset of MLL oncoproteins (DiMartinodownstream targets of wild-type MLL (Yu et al., 1995) and/or
are involved in human leukemia (Owens and Hawley, 2002; van et al., 2000, 2002; Lavau et al., 2000; Luo et al., 2001; Slany et
al., 1998; So and Cleary, 2002, 2003). Here we provide evidenceOostveen et al., 1999). Hematopoietic progenitors transduced
by MLL-GAS7 or vector alone were analyzed for Hox gene for an alternative mechanism involving two different MLL fusion
partners that are normally cytoplasmic proteins, one of whichexpression by RT-PCR at the end of each round of plating in
methylcellulose cultures. Although similar numbers of colonies (Eps15/AF1p) was initially identified as an EGF receptor sub-
strate. While these cytoplasmic proteins do not display inherentwere observed in the first round of plating, cells transduced by
MLL-GAS7 or vector alone exhibited very different Hox gene transactivation properties, they are nonetheless required for
their respective MLL fusion proteins to transform hematopoieticexpression profiles. 5HoxA genes, which have been implicated
in expansion of early hematopoietic progenitors, were mostly progenitors and induce leukemias in mice. AF1p and GAS7
belong to different families of proteins, which have not beendownregulated in the vector-transduced cells. Conversely,
MLL-GAS7-transduced cells expressed a broad array of Hox reported to involve common signaling pathways. Their only
shared features are coiled-coil domains, which are requiredgenes (including HoxA5, A7, A9, and A10) and Hox cofactors
Meis1 and Meis3. Expression of these genes was maintained by the respective MLL-AF1p and MLL-GAS7 oncoproteins for
leukemogenesis. Biochemically, the coiled-coil domains medi-in the second and subsequent platings (Figure 6B). The Hox
gene expression profiles in MLL-GAS7 and MLL-AF1p cultures ate oligomerization of the respective MLL fusion proteins, which
directly correlates with their transformation abilities. In addition,were similar to those of cultures initiated by transduction of
MLL-ENL, whose fusion partner ENL is a component of the forced dimerization of MLL by synthetic dimerization modules
mimics bona fide MLL fusion proteins in altering the growthEBAF mammalian SWI/SNF complex (Nie et al., 2003) and dis-
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Figure 7. Alternative mechanisms for activating the oncogenic potential
of MLL
MLL fusion proteins are schematically shown bound to DNA through their
MLL moieties (MLL). Some nuclear fusion proteins with nuclear partner pro-
teins may function as monomers to recruit accessory factors (arrows)
through the partner protein moiety (X). A subset of cytoplasmic partner
proteins mediates constitutive dimerization/oligomerization to facilitate re-
cruitment of accessory factors in part through the MLL moiety.
properties of myeloid progenitors in vitro. Thus, we conclude
that oligomerization of MLL is a novel mechanism for activating
its oncogenic potential.
Forced homo-oligomerization of MLL by either bona fide
fusion partners or synthetic dimerizers resulted in transcriptional
activation of the HoxA7 promoter, which is likely to be a physio-
logically relevant target for the MLL oncoprotein. Similar trans-
activation readouts have also been observed using reporter
genes with different promoters (Galoian et al., 2000). These
findings are consistent with our observations that expression
of MLL-GAS7 and MLL-AF1p results in maintained expression
of specific Hox genes, which are otherwise repressed in differ-
entiating primary myeloid progenitors. Since similar Hox gene
expression profiles are observed in progenitors transduced with
MLL fusion proteins in which the partner contains a transcrip-
tional effector domain (Ayton and Cleary, 2003), our studies
strongly suggest that oligomerization of MLL may lead to onco-
genic transformation by aberrant recruitment of coactivator
complexes to target genes through the MLL moiety (Figure 7).
This mechanism is consistent with the proposed role of oligo-
merization in recruiting transcriptional repression machinery by
myeloid oncoproteins (Scandura et al., 2002). The oligomeriza-
tion domains of PML (Grignani et al., 1996), PLZF (Dong et al.,
1996), NPM (So et al., 2000), Stat5 (Dong and Tweardy, 2002)
and NuMA (Dong et al., 2003) are essential for transcriptional
repression mediated by the respective RAR
 fusion proteins.
Figure 6. Transcriptional activation mediated by MLL dimerization
A: MLL-GAS7, MLL-AF1p, or cotransfected MLL-zipper constructs activated
transcription from the HoxA7 promoter in transient transfection assays. 293
cells were cotransfected with HoxA7 luciferase reporter and various MLL
fusion constructs (indicated on left) for luciferase assays. Luciferase values
were normalized by LacZ internal control; normalized luciferase values are
shown for the average of three experiments.
B: Hox gene and cofactor expression profiles of cells transduced by vector
alone, MLL-GAS7, or MLL-ENL. RT-PCR analyses were performed on trans-
duced hematopoietic cells harvested at the end of each round of plating
(as indicated at top) in methylcellulose culture or from liquid cultures. Total
RNA from E15.5 embryos served as a positive control.
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Moreover, forced dimerization of RAR
 by synthetic fusion with conserved motifs in MLL are required for dimerization-mediated
oligomerization modules of p53 or p50 NFB results in aberrant enhancement of the growth properties of myeloid progenitors
recruitment of transcriptional repression complexes (Lin and in vitro. One of these domains, CXXC, shares similarity with
Evans, 2000; Minucci et al., 2000). Similarly, the oligomerization DNA methyltransferase and has been shown to mediate binding
domain of ETO in the chimeric transcription factor AML1-ETO to unmethylated, but not methylated, CpG DNA (Birke et al.,
is necessary to recruit transcriptional repressor complexes (Mi- 2002). A second set of DNA binding motifs, the AT hooks, were
nucci et al., 2000). For neither RAR
 nor AML1, however, has not necessary. All other conserved motifs targeted by mutations
oligomerization been shown to be a requirement for cellular were required for dimer-induced transformation, although their
transformation. Our studies extend the role of oligomerization biochemical functions have yet to be determined. Similar MLL
to potential recruitment of activation-associated machinery and requirements were determined recently in a refined structure/
demonstrate the essential role of oligomerization in myeloid function analysis of MLL-ENL (Chen et al., 2002), which is not
transformation mediated by chimeric oncoproteins. known to function as a dimer. Rather, ENL is a component of
Oligomerization may be a critical although not exclusive role EBAF, a mammalian SWI/SNF chromatin remodeling complex,
for cytoplasmic fusion partners of MLL. MLL fusion proteins and MLL-ENL associates with the EBAF complex in leukemia
containing synthetic dimerization modules only modestly altered cells (Nie et al., 2003). Our results suggest that dimerized MLL
the in vitro growth properties of myeloid progenitors, as evi- needs to interact with DNA through both halves of the MLL
denced by enhanced plating efficiencies that could not be sus- moiety, each displaying similar structural requirements as pre-
tained indefinitely, in contrast to the immortalization of progeni- sumed monomeric fusion proteins such as MLL-ENL. Although
tors typically induced by bona fide MLL fusion proteins. This wild-type MLL is not known to dimerize in vivo, the third PHD
may reflect inefficient oligomerization properties of the synthetic finger of MLL is capable of self-interaction in vitro (Fair et al.,
leucine zipper and FKBP/FRB dimerization modules in vivo. 2001), raising the interesting possibility that MLL transcriptional
However, we also observed that mutants of MLL-GAS7 and activity may normally be regulated by dimerization. Our struc-
MLL-AF1p that contained only their coiled-coil domains dis- ture/function studies may also have implications for the subset
played reduced oncogenic potency in vitro and in vivo compared of myeloid leukemias containing MLL self-fusions, which result
with the respective intact fusion proteins. This suggests that in partial tandem duplication of MLL 5 sequences (Schichman
additional domains present in AF1p and GAS7 may contribute et al., 1995). The region of duplication typically spans the MLL
to the oncogenic process, possibly by assisting in the recruit- domains (AS-rich to CXXC) that we found to be required for the
ment of cofactors to promote the assembly of stable transcrip- growth-altering actions of dimerized MLL. Thus, we hypothesize
tional complexes mediated by oligomerization of the MLL moi- that MLL self-fusion may be functionally equivalent to forced
ety. GAS7 contains a WW domain, which in PCIF1 and the MLL dimerization leading to sustained expression of Hox and
histone methyltransferase Set2 has been implicated in transcrip- other subordinate genes due in part to inappropriate recruitment
tional elongation owing to its specific binding to phosphorylated of accessory factors through the intramolecularly dimerized MLL
serines of the carboxy-terminal domain of RNA polymerase II moiety.
(Fan et al., 2003; Li et al., 2002). In AF1p, the EH hands and In summary, our studies demonstrate a novel mechanism
DPF repeats are well-characterized protein-protein interaction by which a subset of fusion partners activates the oncogenic
domains that are capable of recruiting various functionally im- properties of MLL. The consequences of forced, constitutive
portant proteins (Salcini et al., 1999). The C terminus of AF1p MLL dimerization on subordinate Hox genes associated with
also contains two functionally conserved ubiquitin interaction myeloid leukemic transformation appear similar to those dis-
motifs (UIMs) (Polo et al., 2002), which are important for mediat- played by MLL fusion with nuclear partners. Since coiled-coil
ing ubiquitination that has been recently implicated in epigenetic or dimerization domains are present in other MLL fusion partners
regulation of gene expression (Sun and Allis, 2002). Another (Prasad et al., 1994; Chaplin et al., 1995; So et al., 1997; Kuefer
possibility is that these domains in the context of MLL fusion et al., 2003), oligomerization of MLL may be a general oncogenic
proteins may have transdominant antagonistic effects on growth mechanism that merits further studies to establish its prevalence
control pathways normally regulated by the partner protein and, in human leukemias.
thus, facilitate the transformation process. Indeed, disturbances
of AF1p and GAS7 expression have been implicated in deregu- Experimental procedures
lated cell growth and differentiation. Forced expression of AF1p
DNA constructstransforms mouse fibroblasts (Fazioli et al., 1993) while elevated
Retroviral constructs were made by cloning of various cDNA fragments oflevels of GAS7 induce growth arrest and cell differentiation (Ju
GAS7 (accession number AB007854), AF1p (accession number U07707),et al., 1998). Intact MLL-AF1p or MLL-GAS7, therefore, may
2FKBP, FRBT2098L (Ariad Pharmaceuticals, Inc) (www.ariad.com/regulationkits)have the capability to interfere with the normal functions of the (Chen et al., 1995; Choi et al., 1996), Acid Zipper, and Base Zipper (Scott
respective partner protein to accelerate leukemogenesis, which et al., 1996) into the NruI and XhoI sites of the MSCV Flag-tagged MLL
has been reported for other MLL fusion proteins (Simone et al., 5 cloning vector, which encodes MLL amino acids 1–1396 as previously
2001; So and Cleary, 2002). Lack of these properties in the described (So and Cleary, 2002). MLL 5 mutant retroviral constructs were
made by PCR or site-directed mutagenesis as previously described (ChenMLL-oligomerization constructs may account for their reduced
et al., 2002). For dimerization studies, cDNA fragments were fused in-frameoncogenic potency. Oligomerization may also account for the
with the HIS-epitope tag in pcDNA4B cloning vector (Invitrogen); Flag-epi-leukemias that arise in MLL-GAL knockin mice with low pene-
tope tagged fusion proteins were expressed using the pcDNA3.1 expression
trance and long latency (Dobson et al., 2000) since GAL is vector (Invitrogen). A GST-GAS7 construct was made by in-frame cloning
a metabolic enzyme that lacks known transcriptional effector of GAS7 cDNA into the pGEX vector (Pharmacia). Gal4 fusion constructs
properties but contains a tetramerization domain. consisted of GAS7 (aa 1–412) and AF1p (aa 72–896) cloned into the EcoRI
sites of pSG424, which encodes the Gal4 DNA binding domain (aa 1–147)A structure/function analysis demonstrated that several
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(DBD). All constructs were sequenced to exclude mutations introduced by control plasmid and the luciferase reporter construct. Luciferase activities
PCR. were normalized based on -galactosidase levels. Means and standard
deviations were determined from at least two independent experiments
performed in duplicate.Hematopoietic progenitor transformation
and tumorigenicity assays
Hematopoietic progenitor transformation assays were performed as pre- In vitro and in vivo interaction studies
viously described (So et al., 2003). Briefly, viral supernatants were collected GST pulldowns and immunoprecipitation-Western blot (IP-WB) assays were
60 hr after transfection of Phoenix cells and used to infect hematopoietic performed as previously described (So and Cleary, 2002). Briefly, [35S] methi-
progenitors and stem cells that were positively selected for c-Kit expression onine-labeled GAS7 proteins were generated by in vitro transcription and
by magnetic activated cell sorting (MACS). Donor cells were harvested from translation using the TNT-coupled reticulocyte lysate system according to
the bone marrows of 4- to 10-week-old wild-type C57BL/6 mice. After the manufacturer’s instructions (Promega). GST fusion protein (1 g) was
spinoculation by centrifugation at 500  g for 2 hr at 32C, transduced cells preincubated with glutathionine-Sepharose beads (Sigma) in NETN buffer
were cultured overnight in RPMI supplemented with 10% FCS and 20 ng/ (0.5% [v/v] Nonidet P-40, 20 mM Tris/HCl [pH 8.0], 100 mM NaCl, 1 mM
ml stem cell factor (SCF), and 10 ng/ml each of IL-3 and IL-6 (R&D Systems, EDTA) for 60 min at 4C before [35S] methionine-labeled proteins were added.
Minneapolis, Minnesota). Transduced cells were then plated in 1% methyl- After 90 min incubation at 4C, the beads were washed five times in buffer
cellulose (Stem Cell Technologies, Vancouver, BC, Canada) supplemented H (20 mM Hepes [pH 7.7], 50 mM KCl, 20% [v/v] glycerol, 0.1% [v/v] Nonidet
with the same cytokines plus 10 ng/ml GM-CSF (R&D Systems) in the pres- P40, 0.007% -mercaptoethanol). Bound proteins were eluted by boiling in
ence or absence of appropriate drug selection (i.e., 1 mg/ml G418, 1 g/ SDS/PAGE loading buffer, resolved by electrophoresis, and detected by
ml puromycin, or 1 mg/ml hygromycin). After 7 days culture, colonies were autoradiography. For IP-WB, 293 cells were transfected in 6-well plates with
counted to calculate the transduction efficiency. Single-cell suspensions 1 g of each His-tagged and Flag-tagged construct. Cells harvested 48 hr
(104 cells) of drug-resistant colonies were then replated in methylcellulose posttransfection were subjected to IP-WB using either Catch and Release
media supplemented with the same growth factors. Plating was repeated system (Upstate Biotechnologies) according to the manufacturer’s instruc-
every 7 days. Transformation results were determined from at least two tions or conventional IP-WB procedures as previously described (So and
independent experiments. For tumorigenicity assays, single cell suspensions Cleary, 2002). Briefly, transfected cells were lysed in buffer B (20 mM Hepes,
from each round of replating were expanded in RPMI liquid culture containing pH 7.9, 0.4 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF) for 20 min
20% FCS plus 20% WEHI-conditioned medium. 106 immortalized cells were incubation at 4C. Cell lysates were recovered by centrifugation at 12,000
injected into the retro-orbital venous sinus of 6-week-old syngeneic C57BL/6 g for 15 min and brought to 20% glycerol for immunoprecipitation. three
mice, which had received a sublethal dose of 5.25 Gy total body  irradiation micorgrams D8 anti-His antibody (Santa Cruz Biotechnologies) were incu-
(135Cs). Mice were maintained on antibiotic water to avoid infection and bated with the cell lysates at 4C for 3 hr. Twenty microliters of protein G
monitored for development of leukemia by complete blood count, blood sepharose beads (Pharmacia) were then added to the lysates and incubated
smear, and FACS analysis. Tissues were fixed in buffered formalin, sectioned, for additional 2 hr at 4C before they were washed five times in buffer D
and stained with hematoxylin and eosin (H&E) for histological analysis. (0.5 M KCl, 0.1% Tween 20, 0.5 mM DTT, 0.2 mM EDTA). Precipitated
proteins were then denatured at 100C for 5 min and separated by polyacryl-
Phenotype analysis amide gel electrophoresis before transfer to ECL membranes (Amersham)
Immunophenotypic analysis was performed by FACS using fluorochrome- and blotting with M2 anti-Flag antibody (Sigma).
conjugated monoclonal antibodies to Sca-1 (D7 clone), c-Kit (2B8 clone),
Mac-1 (M1/70 clone), Gr-1 (RB6-8C5 clone), B220 (RA3-6B2 clone), and Acknowledgments
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Transcriptional transactivation assays
293 or COS7 cells (5  104) were seeded overnight in 24-well plates before References
transfection of DNA constructs using Fugene (Roche Molecular Biochemi-
cals). Gal4 fusion constructs (0.1 g) were cotransfected with pcDNA3.1/
Ayton, P.M., and Cleary, M.L. (2001). Molecular mechanisms of leukemogen-LacZ internal control plasmid (0.2 g) and a luciferase reporter construct
esis mediated by MLL fusion proteins. Oncogene 20, 5695–5707.(0.2 g), which contained two tandem copies of Gal4 consensus binding
sites and the luciferase gene driven by either a herpes simplex virus thymidine Ayton, P.M., and Cleary, M.L. (2003). Transformation of myeloid progenitors
kinase (TK), adenovirus E1b, or myelomonocytic growth factor promoter (So by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev., in
and Cleary, 2002, 2003). REH cells (5  106) were electroporated with 0.8 press.
g of each Gal4-DBD fusion construct and luciferase reporter construct
Bernard, O.A., Mauchauffe, M., Mecucci, C., Van den Berghe, H., and Berger,together with 0.4 g of pcDNA3.1/LacZ in RPMI containing 10 g of DEAE-
R. (1994). A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is notdextran at 300 V and 960 F in a 0.4 mm cuvette (Bio-Rad electroporator).
related to AF-4, AF-9 nor ENL. Oncogene 9, 1039–1045.Twenty-four hours after transfection, luciferase and -galactosidase activi-
ties were analyzed using commercially prepared reagents. Similar proce- Birke, M., Schreiner, S., Garcia-Cuellar, M.P., Mahr, K., Titgemeyer, F., and
dures were employed for transactivation studies using the HoxA7 Luc-report- Slany, R.K. (2002). The MT domain of the proto-oncoprotein MLL binds to
ers (DiMartino et al., 2002; Schreiner et al., 1999) except that 0.3 g of MLL CpG-containing DNA and discriminates against methylation. Nucleic Acids
Res. 30, 958–965.fusion construct was cotransfected with 0.1 g of each pcDNA3.1/LacZ
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